Skip to main content

News

You are here

Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study

Tuesday, July 1, 2014

New Efficacy Data Adds to Successful Phase 3 Clinical Trial Program Results for Single-Dose Oral Cholera Vaccine for Travelers' Market and People in the Developing World

PaxVax
REDWOOD CITY, Calif.  – PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, July 1 announced positive efficacy results from the 90-day challenge studies of its single-dose oral cholera vaccine candidate, PXVX0200, which utilizes the same attenuated vaccine strain (CVD 103-HgR) previously approved and marketed in several countries under the brand name Orochol. Trial investigators compared the rate of diarrhea in participants vaccinated with PXVX0200 to the rate in participants who had received placebo.

Vaccine efficacy was evaluated by immunizing volunteer participants with an oral dose of the PXVX0200 vaccine or placebo and then subsequently exposing them to the cholera-causing agent (Vibrio cholerae O1 El Tor). Volunteer participants in this challenge study were divided into two groups – the first group was vaccinated and then challenged at 10 days after vaccination, and a second, separate group of volunteer participants was challenged at 90 days post vaccination to further evaluate duration of vaccine protection. Read more.